881995-70-6

Basic information

• Product Name: (Z)-Methyl 3-aMino-4-(2,4,5-trifluorophenyl)but-2-enoate
• Synonyms: (Z)-Methyl 3-aMino-4-(2,4,5-trifluorophenyl)but-2-enoate;2-Butenoic acid, 3-aMino-4-(2,4,5-trifluorophenyl)-, Methyl ester, (2Z)-
• CAS NO: 881995-70-6
• Molecular Formula: C₁₁H₁₀F₃NO₂
• Molecular Weight: 245.1978096
• EINECS: -0
• Mol File: 881995-70-6.mol
• Article Data: 6

Chemical Properties

• Melting Point: 70-71 °C
• Boiling Point: 347.4±42.0 °C(Predicted)
• Appearance: /
• Density: 1.325±0.06 g/cm3(Predicted)
• PKA: 3.95±0.70(Predicted)
• CAS DataBase Reference: (Z)-Methyl 3-aMino-4-(2,4,5-trifluorophenyl)but-2-enoate(CAS DataBase Reference)
• NIST Chemistry Reference: (Z)-Methyl 3-aMino-4-(2,4,5-trifluorophenyl)but-2-enoate(881995-70-6)
• EPA Substance Registry System: (Z)-Methyl 3-aMino-4-(2,4,5-trifluorophenyl)but-2-enoate(881995-70-6)

Safety Data

• Hazardous Substances Data: 881995-70-6(Hazardous Substances Data)

Usage

General Description

(Z)-Methyl 3-amino-4-(2,4,5-trifluorophenyl)but-2-enoate is a chemical compound that falls under the category of organic compounds. It is a derivative of 2,4,5-trifluorophenylbut-2-enoic acid and is commonly used in the field of medicinal chemistry. (Z)-Methyl 3-aMino-4-(2,4,5-trifluorophenyl)but-2-enoate is a potent inhibitor of human cytochrome P450 (CYP) 17A1, which is involved in the biosynthesis of steroid hormones. It has also shown potential as a therapeutic agent for the treatment of hormone-dependent cancers, including prostate cancer. Furthermore, it has demonstrated anti-inflammatory and analgesic properties, making it a promising candidate for the development of new pharmaceutical drugs.

Upstream product

• 769195-26-8 4-(2,4,5-trifluoro-phenyl)-3-oxo-butyric acid methyl ester 
• 209995-38-0 (2,4,5-trifluorophenyl)acetic acid 
• 764667-64-3 5-(1-hydroxy-2-(2,4,5-trifluorophenyl)ethylidene)-2,2-dimethyl-1,3-dioxane-4,6-dione 
• 67-56-1 methanol 

Downstream Products

• 881995-69-3 (R)-3-amino-4-(2,4,5-trifluorophenyl)butyric acid methyl ester 
• 881995-73-9 3-(R)-tert-butoxycarbonylamino-4-(2,4,5-trifluorophenyl)butyric acid methyl ester 
• 1234321-81-3 (Z)-3-acetylamino-4-(2,4,5-trifluorophenyl)-2-butenoic acid methyl ester 
• 1234321-77-7 (Z)-3-tert-butoxycarbonylamino-4-(2,4,5-trifluorophenyl)-2-butenoic acid methyl ester 
• 1253055-92-3 methyl 3-amino-4-(2,4,5-trifluorophenyl)butanoate 
• 486460-00-8 (3R)-3-[(1,1-dimethylethoxycarbonyl)amino]-4-(2,4,5-trifluorophenyl)butanoic acid 
• 486460-32-6 sitagliptin 
• 486460-23-5 (R)-tert-butyl 4-oxo-4-(3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)-1-(2,4,5-trifluorophenyl)butan-2-ylcarbamate 

Relevant articles and documents

Preparation method of chiral 4 - aryl - β β-amino acid derivative

Provided is a method for preparing a chiral 4-aryl-β-amino acid derivative. The preparation method comprises hydrogenating an enamine compound having a structure as shown in Formula III in an organic solvent in the presence of a catalyst containing a transition metal and BIBOPs. The preparation method of the present invention uses a small amount of a selected asymmetric catalyst, and has a simple operation, mild reaction conditions, a high yield, a high stereoselectivity, and better industrial application and economic values.

SITAGLIPTIN SYNTHESIS

The present invention relates to novel processes for the preparation of enantiomerically enriched β-amino acid derivatives such as β-amino esters useful for the synthesis of enantiomerically enriched biologically active molecules such as sitagliptin. The key step involves the resolution of the racemate with mandelic acid.

SITAGLIPTIN SYNTHESIS

The present invention relates to novel processes for the preparation of enantiomerically enriched β -amino acid derivatives such as β -amino esters useful for the synthesis of enantiomerically enriched biologically active molecules such as sitagliptin. The key step involves the resolution of the racemate with mandelic acid.